...
首页> 外文期刊>Bioscience, Biotechnology, and Biochemistry >Laboratory-scale production of (S)-reticuline, an important intermediate of benzylisoquinoline alkaloids, using a bacterial-based method
【24h】

Laboratory-scale production of (S)-reticuline, an important intermediate of benzylisoquinoline alkaloids, using a bacterial-based method

机译:实验室规模生产(S) - 苄基异喹啉生物碱的重要中间体,使用基于细菌的方法

获取原文
获取原文并翻译 | 示例

摘要

Benzylisoquinoline alkaloids (BIAs) are a group of plant secondary metabolites that have been identified as targets for drug discovery because of their diverse pharmaceutical activities. Well-known BIAs are relatively abundant in plants and have therefore been extensively studied. However, although unknown BIAs are also thought to have valuable activities, they are difficult to obtain because the raw materials are present at low abundance in nature. We have previously reported the fermentative production of an important intermediate (S)-reticuline from dopamine using Escherichia coli. However, the yield is typically limited. Here, we improved production efficiency by combining in vivo tetrahydropapaveroline production in E. coli with in vitro enzymatic synthesis of (S)-reticuline. Finally, 593mg of pure (S)-reticuline was obtained from 1 L of the reaction mixture. Because this bacterial-based method is simple, it could be widely used for production of (S)-reticuline and related BIAs, thereby facilitating studies of BIAs for drug discovery.
机译:苄基异喹啉生物碱(偏见)是一组植物次级代谢产物,其被鉴定为药物发现的靶标,因为它们不同的药物活动。众所周知的偏见在植物中相对丰富,因此已经广泛研究。然而,尽管未知的偏见也被认为具有有价值的活动,但难以获得,因为原材料本质上的低丰度存在。我们之前报道了使用大肠杆菌的多巴胺的重要中间体的发酵生产 - 使用大肠杆菌。然而,产量通常是有限的。在这里,我们通过在大肠杆菌中与体外酶合成的体外酶合成组合来改善生产效率。最后,从1L的反应混合物中获得593mg纯净的纯度。因为这种基于细菌的方法很简单,所以可以广泛用于生产 - 培养和相关偏差,从而促进对药物发现的偏差的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号